Health Care & Life Sciences » Healthcare Provision | Shin Nippon Biomedical Laboratories Ltd.

Shin Nippon Biomedical Laboratories Ltd. | Key People and Executives

Ryoichi Nagata
Chairman, President & Chief Executive Officer
Ken Takanashi
COO, Representative Director & Vice President
Shinji Nitanda
Chief Financial Officer & Managing Director
Hideyuki Hirama
Managing Director & Chief Strategy Officer
Kazumi Uchi
Director, Head-Finance & Accounting
Satoshi Matsumoto
MD, Head-General Affairs & Personnel
Koichiro Fukuzaki
Vice Chairman
Shinichi Fukumoto
Independent Outside Director
Takashi Yamashita
Independent Outside Director
Ryoichi Nagata
Chairman, President & Chief Executive Officer
Ken Takanashi
COO, Representative Director & Vice President
Shinji Nitanda
Chief Financial Officer & Managing Director
Jun Ozaki
Executive Officer
Hideyuki Hirama
Managing Director & Chief Strategy Officer
Kazumi Uchi
Director, Head-Finance & Accounting
Hidenobu Samejima
Senior Managing Executive Officer
Shuichi Kanazashi
Managing Executive Officer
Shunji Haruta
Executive Officer & Manager-Translational Research
Masahiro Uto
Executive Officer
Satoshi Matsumoto
MD, Head-General Affairs & Personnel
Koichiro Fukuzaki
Vice Chairman
Hideshi Tsusaki
Managing Executive Officer & Senior Head-Sales
Tomoaki Honda
Executive Officer & Senior Manager-Internal Audit
Toshio Onimaru
Auditor
Toshihiko Makino
Executive Officer
Chise Kanda
Investor Relations Contact
Shinichi Fukumoto
Independent Outside Director
Takashi Yamashita
Independent Outside Director

About Shin Nippon Biomedical Laboratories

View Profile
Address
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.snbl.co.jp
Updated 07/08/2019
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells.